ABVX (Abivax) Total Liabilities: $135.89 Mil (As of Mar. 2026)


ABVX Abivax SA ABVX
10 GF Score
Price $144.66
! 2 Warning Signs
View Full Analysis

What is Abivax Total Liabilities?

Abivax ABVX +9.12% 10 Total Liabilities is $135.89 Mil as of Mar. 2026. GuruFocus rates ABVX with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Abivax's Total Liabilities for the quarter that ended in Mar. 2026 was $135.89 Mil.

Abivax's quarterly Total Liabilities declined from Sep. 2025 ($165.28 Mil) to Dec. 2025 ($151.21 Mil) and declined from Dec. 2025 ($151.21 Mil) to Mar. 2026 ($135.89 Mil).

Abivax's annual Total Liabilities increased from Dec. 2023 ($142.91 Mil) to Dec. 2024 ($172.40 Mil) but then declined from Dec. 2024 ($172.40 Mil) to Dec. 2025 ($151.21 Mil).

Abivax Total Liabilities Historical Data

* Premium members only.

The historical data trend for Abivax's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abivax Total Liabilities Chart

Abivax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.12 72.41 142.91 172.40 151.21

Abivax Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.60 193.68 165.28 151.21 135.89
ABVX
10GF Score
Abivax SA ABVX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abivax Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Abivax's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=73.795+(0.649+69.187
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+6.848+0.734+0)
=151.21

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=684.24-533.027
=151.21

Abivax's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=71.946+(0.4+55.786
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+7.024+0.738+0)
=135.89

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=632.534-496.64
=135.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $135.89 Mil mean?
Abivax (ABVX) has a Total Liabilities of $135.89 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Abivax and its competitors.
Is Abivax's Total Liabilities too high?
Abivax's current Total Liabilities is $135.89 Mil. Overall, Abivax has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Abivax's Total Liabilities compare to VRTX and REGN?
Abivax's Total Liabilities of $135.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Abivax and its competitors. Abivax's current Total Liabilities is $135.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abivax stock overvalued right now?
Abivax (ABVX) has a current Total Liabilities of $135.89 Mil. The current Total Liabilities is $135.89 Mil. Abivax's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Abivax (ABVX), the current Total Liabilities is $135.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Abivax Business Description

Address 7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
10GF Score

Get the complete analysis for ABVX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$144.66
Price